InsidersTradesSigma
Track the Immuneering Corp stock price and the full insider trade history of the company, a listed issuer based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Immuneering Corp has logged 64 reports. Market capitalisation: €284m. The latest transaction was reported on 24 June 2026 (Acquisition). Among the most active insiders: Feinberg Peter. The full history is free.
64
Insider Decl.
n/a
Thresholds
€1m
42 ops.
Buy Volume
€1m
2 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Immuneering Corp Strong Buy (bullish), based on 7 analysts. Average price target: US$18.86.
49Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 24 June 2026
Declarations64 total
2,400 sharesClass A Common StockSEC:0001790340-26-000078:0
Canonical exit: 21 Sept 2026 (T+90)
3,628 shares@ US$4.292554.3% of flowClass A Common StockSEC:0001790340-26-000044:0
5,250 shares@ US$4.7661.6% of flowClass A Common StockSEC:0001790340-26-000016:0
Canonical exit: 16 Apr 2026 (T+90)
21,645 shares@ US$4.668143.2% of flowClass A Common StockSEC:0001790340-26-000014:0
Canonical exit: 15 Apr 2026 (T+90)
2,298 shares@ US$4.5712.8% of flowClass A Common StockSEC:0001790340-26-000012:0
Canonical exit: 15 Apr 2026 (T+90)
2,626 shares@ US$4.15317.7% of flowClass A Common StockSEC:0001790340-26-000010:0
Canonical exit: 13 Apr 2026 (T+90)
20,000 shares@ US$4.345211.6% of flowClass A Common StockSEC:0001790340-26-000008:0
Canonical exit: 12 Apr 2026 (T+90)
7,500 shares@ US$6.677.5% of flowClass A Common StockSEC:0001790340-25-000127:0
Canonical exit: 1 Jan 2026 (T+90)
300 shares@ US$6.395.1% of flowClass A Common StockSEC:0001790340-25-000125:0
Canonical exit: 30 Dec 2025 (T+90)
800 shares@ US$6.379210.0% of flowClass A Common StockSEC:0001790340-25-000123:0
Canonical exit: 30 Dec 2025 (T+90)
1,020 shares@ US$6.829919.5% of flowClass A Common StockSEC:0001790340-25-000121:0
Canonical exit: 30 Dec 2025 (T+90)
7,500 shares@ US$7.03078.5% of flowClass A Common StockSEC:0001790340-25-000119:0
Canonical exit: 29 Dec 2025 (T+90)
5,000 shares@ US$7.185.8% of flowClass A Common StockSEC:0001790340-25-000117:0
Canonical exit: 28 Dec 2025 (T+90)
11,815 shares@ US$1.42836.6% of flowClass A Common StockSEC:0001790340-25-000115:0
14,497 shares@ US$1.42857.5% of flowClass A Common StockSEC:0001790340-25-000113:0
14,880 shares@ US$1.42829.3% of flowClass A Common StockSEC:0001790340-25-000111:0
2,500 shares@ US$3.5956100.0% of flowClass A Common StockSEC:0001790340-25-000098:0
Canonical exit: 30 Sept 2025 (T+90)
700 shares@ US$3.569518.6% of flowClass A Common StockSEC:0001790340-25-000096:0
Canonical exit: 30 Sept 2025 (T+90)
2,985 shares@ US$3.37924.7% of flowClass A Common StockSEC:0001790340-25-000094:0
Canonical exit: 29 Sept 2025 (T+90)
9,500 shares@ US$3.661926.0% of flowClass A Common StockSEC:0001790340-25-000089:0
Canonical exit: 25 Sept 2025 (T+90)
7,415 shares@ US$2.699940.0% of flowClass A Common StockSEC:0001790340-25-000087:0
Canonical exit: 18 Sept 2025 (T+90)
1,900 shares@ US$2.528531.2% of flowClass A Common StockSEC:0001790340-25-000085:0
Canonical exit: 18 Sept 2025 (T+90)
25,000 shares@ US$2.527512.1% of flowClass A Common StockSEC:0001790340-25-000083:0
Canonical exit: 16 Sept 2025 (T+90)
21,000 shares@ US$2.387825.0% of flowClass A Common StockSEC:0001790340-25-000081:0
Canonical exit: 16 Sept 2025 (T+90)
40,485 shares@ US$2.205292.0% of flowClass A Common StockSEC:0001790340-25-000079:0
Canonical exit: 15 Sept 2025 (T+90)
25 of 64 declarations
关于 Immuneering Corp
Immuneering Corp 是一家美国生物技术公司，在纳斯达克（美国）上市，股票代码为 IMRX。它定位为一家临床阶段肿瘤公司，专注于开发旨在改善患者生存率和耐受性的癌症疗法。公司总部位于马萨诸塞州剑桥，围绕计算生物学和信号动力学方法进行药物发现，目标是设计能够抑制肿瘤通路同时限制对健康细胞损害的药物。对于国际投资者而言，这是一个经典的开发阶段生物制药案例：具有高执行和临床风险，但如果其主要项目持续提供令人信服的数据，则具有可观的上涨潜力。（[ir.immuneering.com](https://ir.immuneering.com/investor-relations?utm_source=openai)） Immuneering 的核心价值主张是其“深度周期抑制剂”平台，公司将其描述为一种脉冲通路抑制策略，旨在超越肿瘤适应。其主要候选药物是 atebimetinib，也称为 IMM-1-104，一种口服、每日一次的 MEK 抑制剂。管理层强调了该项目在 MAPK 通路驱动的癌症中的潜力，包括胰腺癌和其他具有 RAS 突变的实体瘤。公司还拥有早期阶段的项目，使其在一定程度上实现了有限但相关的管线多元化。（[ir.immuneering.com](https://ir.immuneering.com/investor-relations?utm_source=openai)） 从竞争角度来看，Immuneering 在一个拥挤的肿瘤领域运营，该领域由大型制药公司、专业肿瘤生物技术公司和多个靶向治疗平台主导。其差异化不在于规模，而在于其科学方法以及解决大量未满足患者群体需求的可能性。理论上，该平台的多适应症潜力可以拓宽机会范围，超越单一肿瘤类型。然而，实际上，股权故事仍然高度依赖于临床结果、耐受性以及公司通过管线下一阶段持续为开发提供资金的能力。（[ir.immuneering.com](https://ir.immuneering.com/investor-relations?utm_source=openai)） 从地理上看，Immuneering 的业务主要以美国为中心，其运营和科学基地位于马萨诸塞州剑桥地区。近期里程碑强调了资本市场和临床开发密集阶段：IMM-1-104 在一线胰腺癌中的2a期试验更新、投资者会议参与以及2025年的大量融资活动，包括私募和大规模股权发行以支持临床前和临床进展。对于欧洲投资者而言，IMRX 应被视为由临床催化剂和监管里程碑驱动的投机性增长股票，但其具有明确阐述的科学论点，并在肿瘤领域日益受到关注。（[ir.immuneering.com](https://ir.immuneering.com/news-releases/news-release-details/immuneering-reports-fourth-quarter-and-full-year-2025-financial?utm_source=openai)）
